Pomerantz LLP investigates GSK securities fraud claims.

Pomerantz LLP is investigating claims of securities fraud against GSK plc, focusing on the company's announcement of a negative FDA advisory committee vote for its drug Blenrep. The news led to a 4.73% drop in GSK's American Depositary Receipt price. Investors who held GSK shares are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

September 02, 2025

Pomerantz LLP has initiated an investigation into GSK plc (GSK) for potential securities fraud or unlawful business practices. The probe centers on the company's July 2025 press release, which announced a negative FDA advisory committee vote on its Blenrep drug. This announcement resulted in a 4.73% drop in GSK's American Depositary Receipt (ADR) price.

Investors who held GSK shares during the time of the Blenrep announcement are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation is ongoing and aims to determine if the company engaged in any fraudulent or illegal activities related to the Blenrep announcement.

Despite the ongoing investigation, GSK has received a significant boost with the UK approval of Blujepa, a novel oral antibiotic designed to treat uncomplicated urinary tract infections. This approval marks a milestone in GSK's innovative portfolio, as it introduces the first new class of oral antibiotics in several decades. Analysts are cautiously optimistic about the implications of this approval. The average one-year price target for GSK plc is $38.39, with predictions ranging from $45.00 to $33.91, suggesting a potential downside of 3.81% from the current price of $39.91.

GuruFocus estimates suggest a GF Value of $44.64 for GSK plc in one year, projecting an upside potential of 11.85% from the current price. Despite the positive outlook, investors should remain vigilant due to the ongoing investigation by Pomerantz LLP.

References:
[1] https://www.gurufocus.com/news/3083978/gsk-gsk-receives-uk-approval-for-new-antibiotic-blujepa